Gastrointe?stinal Therapeuti?cs Industry: Promising Drugs in Late-Stage Developmen?t Could Stabilise Declining Global Market
The gastrointestinal (GI) therapeutics market for irritable bowel syndrome (IBS), ulcerative colitis (UC), and Crohn’s disease (CD) in the eight major markets (8MM) — the US, UK, France, Germany, Italy, Spain, Canada and Japan — is expected to decrease in value from $6.8 billion in 2012 to $6.6 billion by 2019, at a negative Compound Annual Growth Rate (CAGR) of 0.3%, forecasts business intelligence provider GBI Research.
According to the firm’s latest report*, the GI market will register different CAGRs across the 8MM during the forecast period. The US and Japan will witness positive CAGRs of 0.2% and 4%, respectively, while the European markets will decline at a negative CAGR of 2.5%. This unfavourable growth is due to the upcoming patent expiry of various major drugs.
Arti Singh, Analyst for GBI Research, says: “As Humira and Remicade account for a substantial share of the GI therapeutics industry, their patent expiries will harm the overall market value. The entry of generics and biosimilars will also have a strong impact on sales.”
However, promising pipeline drugs in the late stages of development could stabilize the current market.
Singh continues: “Three molecules in the pre-registration stage of development are expected to be approved during the forecast period. Of these molecules, one — vedolizumab — is indicated for the treatment of both UC and CD. The second molecule is a biosimilar of blockbuster drug Remicade (infliximab) and is expected to be launched following Remicade’s patent expiry.”
In addition, almost 51% of the overall GI pipeline is in Phase II and Phase III development, of which 19 molecules are indicated for the treatment of IBS, 48 for UC and 41 for CD.
“The major factors currently stabilizing the market include the increasing prevalence of GI diseases, growing awareness of the importance of detecting these diseases early and the availability of effective diagnostics,” the analyst concludes.
Related News
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.